Tag: CDSCO news
CDSCO Reveals 5.5% of Drug Samples Not Meeting Standards in October 2023
In a recent revelation by the Central Drugs Standard Control Organisation (CDSCO), nearly 5.5% of drug samples tested…
DCGI launches an investigation into antipsychotic drugs made without authorization.
In its most recent meeting, the National Pharmaceutical Pricing Authority (NPPA) set a ceiling price for the antipsychotic…
Sequana Medical’s IND application to begin the phase 1/2a MOJAVE study with DSR 2.0 to treat congestive heart failure has been approved by the US FDA.
The US Food and Drug Administration (FDA) has approved Sequana Medical NV’s investigational new drug (IND) application for…
AiMeD appreciates the National Medical Devices Policy 2023’s cabinet approval.
The Central Government’s decision to approve the much-needed National Medical Devices Policy (NMDP), 2023, has been applauded by…
New US FDA certifications for Abbott’s life support system will enable medical professionals to treat more seriously ill patients.
The US Food and Drug Administration (FDA) recently granted Abbott two more clearances for the company’s market-leading life…
PCI instructs new institutions to submit SIF using Google form due to technical difficulties with its online portal.
Following the earlier attempt to invite applications through its portal failing due to some technical issues, the Pharmacy…
The UK MHRA has approved the chemotherapeutic medication Cisplatin from Venus Remedies for marketing.
Cisplatin, a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer, and bladder carcinoma,…
To evaluate the PEF rate of lung function in asthma patients, Tenovi develops a cellular remote Peak Flow Metre that has been approved by the US FDA.
Tenovi offers Tenovi, a leader in US FDA-approved remote patient monitoring (RPM) solutions, recently announced the release of…
DCO India will begin a nationwide push to encourage the usage of generic medications.
The Drug Control Officers Welfare Association (DCO India) is preparing a pan-Indian campaign to amplify and promote the…
In persons with certain forms of adjuvant liver cancer, Roche reports that the Tecentriq + Avastin phase III IMbrave050 research lowers the likelihood of the cancer coming back.
Avastin (bevacizumab) plus Tecentriq (atezolizumab) showed a statistically significant improvement in recurrence-free survival (RFS) in patients with hepatocellular…
Registration Form
This will close in 0 seconds
